Aanastra Inc to Showcase its Peptide-RNA Therapeutics Technology in Multiple Presentations at the American Society for Gene and Cell Therapies (ASGCT) Annual Meeting 2024
02 Mayo 2024 - 5:30AM
Aanastra, Inc., a biopharmaceutical company focused on developing
RNA therapeutics leveraging its peptide delivery technology for
targeting cancers and other genetic diseases, today announced
multiple presentations at the 2024 American Society for Gene
and Cell Therapies (ASGCT), taking place May 7-11, 2024,
in Baltimore, MD.
ASGCT presentation details are below:
Title (Poster): "Peptide Based
Nanoparticle-Platform for Extrahepatic Delivery of Functional
mRNAs"Session Title: Other Nonviral
DeliveryLocation: Exhibit
HallAbstract
Number: 761Date/Time: Wednesday
May 8, 2024, 12:00 PMPresenting
Author: DIVITA Gilles, PhD
Title (Poster): "Peptide-Based
Nanoparticles Mediated mRNA Rescue of Factor VIII; a New Approach
to Treat Hemophilia A"Session Title: Liver Genetic
DiseasesLocation: Exhibit
HallAbstract
Number: 1093Date/Time: Thursday
May 9, 2024, 12:00 PMPresenting Author:
DIVITA Gilles, PhD
Title (Poster): "In Vivo CRISPR Mediated
Editing of PCSK9 Using Peptide-Based Nanoparticles Durably Lowers
Cholesterol in Mice"Session Title: Liver Genetic
DiseasesLocation: Exhibit
HallAbstract
Number: 1094Date/Time: Thursday
May 9, 2024, 12:00 PMPresenting Author:
DIVITA Gilles, PhD
Title (Oral Presentation): "KRAS Mutant
Gene Editing Abolishes Tumor Growth In Vivo and Overcomes Acquired
Resistance to KRASG12C and KRASG12D Small Molecule
Inhibitors"Session Title: Targeted Gene and Cell
Therapy IILocation: Room
318-323Abstract
Number: 415Date/Time: Saturday
May 11, 2024, 10:15 AM - 12:00 PMPresenting
Author: DESAI Neil, PhD
More information can be found on the ASGCT
meeting website.
About Aanastra, Inc.
Aanastra Inc (formerly Aadigen Inc) is a start-up
biopharmaceutical company focused on treating cancer using its
novel RNA therapeutics strategy to target aberrant Tumor Suppressor
Genes and Oncogenes. Aanastra’s technology has also been used to
target other genetic diseases. The technology driving Aanastra’s
approach is based on proprietary RNA combined with proprietary
peptides that are able to target various tissues and tumors in vivo
unlike commonly used strategies for RNA delivery including viral
and lipid-based methods.
Aanastra’s strategy for aberrant Tumor Suppressor Rescue using
proprietary mRNA and gene editing of mutated Oncogenes have shown
remarkable antitumor effects in animal models of various cancers
that have mutated P53, KRAS or BRCA1. The utility of Aanastra’s
technology has also been demonstrated outside of cancer in animal
models of hemophilia A to normalize Factor VIII levels and in
cholesterol lowering applications by targeting PCSK9.
Aanastra (Los Angeles, CA) works closely with its sister company
Divincell SAS (Nimes, France) in the development of its RNA
therapeutics. More information on the Company's strategy is
available on the Aanastra website at www.aanastra.com and
connect with us on LinkedIn.
Contact:
IR@aanastra.com